Bioidentical Hormones Market

Growing prevalence of hormonal deficiencies is driving the market growth

Market CAGR for bioidentical hormones is driven by the rising number of people suffering from hormonal deficiencies. The commonality of growth hormone and metabolic hormone deficits influences the market. The need for hormone biosimilars is growing as the treatments for illnesses connected to hormones change over time, and hormonal shortages become more common. For example, in January 2022, the British Medical Journal, a peer-reviewed medical trade publication in the UK, reported that the prevalence of GH deficit (GHD) in children is estimated to range from 1 in 3500 to 1 in 10000 worldwide.

Additionally, 6,000 persons in the USA are anticipated to receive a diagnosis of growth hormone (GH) deficiency in June 2022, according to Medscape research. The market for biosimilar hormones is driven by the expanding need to treat individuals with ongoing hormonal deficits.

One of the most prevalent gynecological problems in women is menopause. Contrarily, growth hormone is also thought to be a rare endocrine condition that manifests in adults as a lack of energy, insulin resistance, abnormal lipid levels, and a low level of physical activity. According to Journal of Clinical Endocrinology & Metabolism, Langerhans cell histiocytosis patients have a high prevalence of the growth hormone disorder, which further causes diabetic insipidus and results in growth hormone deficiency in patients with diabetes insipidus. Global acceptance of these medicines has increased due to the rise in adult incidence of hormone insufficiency.

With the right dosage, GHRT shows a low frequency of side effects and improves most GH-deficient changes.  Strong adoption of new goods and successful launch strategies for developing the product line drive market growth during the projection period. With the right dosage, GHRT shows a low frequency of side effects and improves most GH-deficient changes.  Strong adoption of new goods and successful launch strategies for developing the product line drive market growth during the projection period. Thus, driving the bioidentical hormones market revenue.

The Global Bioidentical Hormones Market Industry is projected to experience substantial growth, with estimates indicating a rise from 2.37 USD Billion in 2024 to 4.37 USD Billion by 2035. This growth trajectory suggests a robust compound annual growth rate (CAGR) of 5.72% from 2025 to 2035. Such projections reflect the increasing demand for personalized hormone therapies and the expanding awareness of hormonal health. The market's evolution is likely to be influenced by various factors, including advancements in technology, regulatory support, and the growing aging population, all contributing to a favorable environment for bioidentical hormone therapies.

The Global Bioidentical Hormones Market Industry is experiencing growth driven by the increasing aging population. As individuals age, they often encounter hormonal imbalances that can lead to various health issues. Bioidentical hormones offer a solution to alleviate symptoms associated with menopause and andropause. In 2024, the market is projected to reach 2.37 USD Billion, reflecting the rising demand for personalized hormone therapies. This trend is expected to continue as the global population aged 60 and above is anticipated to double by 2050, indicating a substantial market opportunity for bioidentical hormone therapies.

There is a notable increase in awareness regarding hormonal health, which is significantly influencing the Global Bioidentical Hormones Market Industry. Educational campaigns and healthcare initiatives are promoting understanding of hormonal imbalances and their effects on overall health. As patients become more informed, they are more likely to seek bioidentical hormone therapies as a viable treatment option. This shift in consumer behavior is likely to contribute to the market's growth, with projections indicating an increase to 4.37 USD Billion by 2035. The emphasis on preventive healthcare further underscores the importance of addressing hormonal health.

The rising incidence of hormonal disorders is a critical driver for the Global Bioidentical Hormones Market Industry. Conditions such as hypothyroidism, polycystic ovary syndrome, and menopause-related symptoms are becoming increasingly prevalent. This trend is likely to escalate the demand for bioidentical hormone therapies as patients seek effective treatment options. The growing recognition of these disorders among healthcare providers and patients alike is fostering a more proactive approach to hormonal health. Consequently, the market is poised for growth, with the potential to reach 4.37 USD Billion by 2035, as more individuals seek tailored hormonal solutions.

Technological advancements in hormone replacement therapy are propelling the Global Bioidentical Hormones Market Industry forward. Innovations in formulation and delivery methods have enhanced the efficacy and safety of bioidentical hormones. For instance, the development of transdermal patches and subcutaneous implants offers patients more convenient options for hormone delivery. These advancements not only improve patient compliance but also expand the potential market reach. As a result, the market is expected to grow at a CAGR of 5.72% from 2025 to 2035, reflecting the ongoing evolution of hormone therapies and their acceptance in mainstream medicine.

Regulatory support for bioidentical hormones is enhancing the credibility and acceptance of these therapies within the Global Bioidentical Hormones Market Industry. Governments and health authorities are increasingly recognizing the benefits of bioidentical hormones, leading to clearer guidelines and regulations. This support not only fosters innovation but also encourages healthcare providers to adopt these therapies in clinical practice. As regulations evolve, the market is likely to witness increased investment and research, further driving growth. The anticipated market expansion to 4.37 USD Billion by 2035 underscores the positive impact of regulatory frameworks on the bioidentical hormone sector.

By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American bioidentical hormones market area will dominate this market. Due to the rising frequency of illnesses related to menopause and growth hormone deficiency and the high knowledge of the therapy among patients aged 35 and older, North America is predicted to dominate the global market. Nearly half of all post-menopausal women in the United States reported using bioidentical hormone therapy at least once throughout their lives, according to the National Institutes of Health (NIH).

Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.

Figure 2: BIOIDENTICAL HORMONES MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe’s bioidentical hormones market accounts for the second-largest market share due to increased growth hormone abnormalities, hypothyroidism in the elderly population, and hormonal disorders in women experiencing menopausal symptoms. Additionally, the increased development of new pharmaceuticals by manufacturers to extend the market globally has stoked the need for drugs in a particular region driving the industry's expansion. Further, the German bioidentical hormones market held the largest market share, and the UK bioidentical hormones market was the rapidly growing market in the European region.

The Asia-Pacific Bioidentical Hormones Market is expected to grow at the fastest CAGR from 2023 to 2032. The prevalence of vasomotor symptoms linked with menopause has been observed to range from 43% to 83% among women in East Asian countries, according to Journal of the North American Menopause Society (May 2022). The region's demand for bioidentical hormone therapy is thus anticipated to increase as more women enter menopause. Moreover, China’s bioidentical hormones market held the largest market share, and the Indian bioidentical hormones market was the rapidly growing market in the Asia-Pacific region.

Leading market players are largely investing in research and development to expand their product lines, which will help the bioidentical hormones market, grow even more. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their global presence. The bioidentical hormones industry must provide affordable products to expand and thrive in a more competitive and challenging market environment.

One of the major business strategies manufacturers use in the global bioidentical hormones industry to increase the market sector and benefit customers is local manufacturing to lower operational costs. In recent years, the bioidentical hormones industry has stipulated some of the most important medicinal benefits.  Major players in the bioidentical hormones industry, including BioTE Medical, Bio station, Neuva Aesthetics, Advantage Pharmaceuticals Inc., SottoPelle, and others, are funding operations for research and development to boost market demand.

Theramex is a London-based pharmaceutical firm specializing in women's health goods such as contraception, fertility, menopause, and osteoporosis. It was founded in 2018 to acquire certain Teva Active Pharmaceutical Ingredients' assets belonging to Theramex Laboratories, a pharmaceutical firm in Monaco. In September 2021, Theramex announced the approval of Bijuva / Bijuve (1mg estradiol / 100mg progesterone) in Europe and the United Kingdom.

The first and only body-identical hormone therapy (HRT) medication, known as Bijuva (Bijuve in the UK), combines progesterone and estradiol in a single daily oral capsule to treat the symptoms of estrogen insufficiency in postmenopausal women with a functioning uterus and a minimum of 12 months since their last menstrual period.

I-MAB Biopharma Co., Ltd. is a pharmaceutical product development and manufacturing company. I-Mab Biopharma is a Chinese clinical-stage biotech startup that plans to IPO on the Nasdaq in January 2020. Its first commercial medicine will likely be eftansomatropin, a long-acting growth hormone with a huge market in China among pediatric patients with low height, and will be available in 2024 or 2025. In November 2021, I-MAB Biopharma Co., Ltd. collaborated with Jumpcan Pharmaceutical Group to develop and market eftansomatropin alfa (TJ101) in China.

TJ101 is a long-lasting recombinant form of human growth hormone that is now being investigated in a phase 3 clinical trial for treating pediatric growth hormone deficiency.  This agreement is intended to help it strengthen its position in the market for bioidentical hormone therapy.